Hansoh BioMedical R&D Company

Quick facts

Marketed products

• Drospirenone and Ethinyl Estradiol tablets · Contraception / Gynecology
  Drospirenone and ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity.

Phase 3 pipeline

• Gemcitabine combined with docetaxel · Oncology
  Gemcitabine and docetaxel work synergistically as chemotherapy agents—gemcitabine inhibits ribonucleotide reductase to disrupt DNA synthesis, while docetaxel stabilizes microtubules to prevent cell division—together targeting rapidly dividing cancer cells.
• HS-10374-matched placebo tablets
  This is a placebo tablet formulation used as a control comparator in clinical trials of HS-10374.
• HS-20089 · Oncology
  HS-20089 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
• HS-20093 · Oncology
  HS-20093 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
• HS-20137 · Oncology
  HS-20137 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
• Placebo&HS-20137
  HS-20137 is a small molecule with an unknown mechanism of action.

Phase 2 pipeline

• HS-10374
• HS-10384 tablet Dose 1
• HS-10390
• HS-20106

Phase 1 pipeline

• HS-10374 tablets
• HS-10384 tablets
• HS-20105
• HS-20108 Monotherapy
• HS-20117 combined HS-20093
• HS-20117 combined HS-20093 and 5-FU

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Hansoh BioMedical R&D Company portfolio CI brief
• Hansoh BioMedical R&D Company pipeline updates RSS

Frequently asked questions about Hansoh BioMedical R&D Company

Related

• Drospirenone and Ethinyl Estradiol tablets · Contraception / Gynecology
• Sector hub: All tracked pharma companies